Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
627 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group M1 | EXPERIMENTAL | dose level 1 of 627 |
| Group M2 | EXPERIMENTAL | dose level 2 of 627 |
| Group M3 | EXPERIMENTAL | dose level 3 of 627 |
| Group M4 | EXPERIMENTAL | dose level 4 of 627 |
| Group A | EXPERIMENTAL | 627 Dose A subcutaneous (SC) injection. |
| Group B | EXPERIMENTAL | 627 Dose B subcutaneous (SC) injection. |
| Placebo | PLACEBO_COMPARATOR | Placebo subcutaneous (SC) injection. |
| Group C | EXPERIMENTAL | 627 subcutaneous (SC) injection. |
| 627 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 627 | DRUG | 627 subcutaneous (SC) injection. |
| Placebo | DRUG | Placebo subcutaneous (SC) injection. |
Inclusion Criteria: 1. Able to understand and comply with the requirements of the study protocol, and sign the written informed consent form (ICF). 2. Male or female subjects aged 18-75 years old when signing the ICF. 3. Subjects must have been diagnosed with UC for at least 3 months prior to rando...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 10 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Upadacitinib |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Tulisokibart |
| Pfizer Inc. | PFE | 8 | PHASE3 | Etrasimod |
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Filgotinib |
| Abivax SA Sponsored ADR | ABVX | 2 | PHASE3 | ABX464 |
| Bristol-Myers Squibb Company | BMY | 5 | PHASE2 | Ozanimod |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Palatin Technologies, Inc. | PTN | 1 | PHASE2 | PL8177 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | GSK4528287 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | XmAb942 |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE2 | 627 |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
627 is an investigational monoclonal antibody being developed for the treatment of ulcerative colitis (UC). It is also being evaluated in healthy subjects to assess its safety and tolerability. The drug is currently in clinical development and has not been approved by regulatory authorities.
627 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being studied for its potential to treat ulcerative colitis, an inflammatory bowel disease, though the exact mechanism of action is not publicly detailed.
627 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company traded on the stock market under the ticker symbol SBFM. The company is conducting clinical trials to evaluate the drug's safety and efficacy in healthy subjects and patients with ulcerative colitis.
627 is in Phase 1 clinical development for healthy subjects and Phase 2 clinical development for ulcerative colitis. The Phase 1 trial is not yet recruiting, while the Phase 2 trial is currently recruiting participants in China. The drug remains investigational and is not yet approved.
627 is being studied in two clinical trials. NCT07065136 is a Phase 1 trial in healthy adult subjects with an enrollment of 108. NCT07507513 is a Phase 2 trial in patients with ulcerative colitis, enrolling 288 participants in China. Both trials are randomized, double-blind, and placebo-controlled.
No alternative names for 627 have been disclosed. The drug is identified solely by its code name 627 in clinical trial registrations and company communications. It is a distinct investigational monoclonal antibody being developed by Sunshine Biopharma Inc.